Skip to main content

Research Repository

Advanced Search

All Outputs (15)

Invasion in breast lesions: the role of the epithelial-stroma barrier (2017)
Journal Article
Rakha, E. A., Miligy, I., Gorringe, K. L., Toss, M. S., Green, A. R., Fox, S. B., …Ellis, I. O. (2018). Invasion in breast lesions: the role of the epithelial-stroma barrier. Histopathology, 72(7), 1075-1083. https://doi.org/10.1111/his.13446

Despite the significant biological, behavioural and management differences between ductal carcinoma in situ (DCIS) and invasive carcinoma of the breast, they share many morphological and molecular similarities. Differentiation of these two different... Read More about Invasion in breast lesions: the role of the epithelial-stroma barrier.

Diagnostic challenges in papillary lesions of the breast (2017)
Journal Article
Rakha, E. A., & Ellis, I. O. (2018). Diagnostic challenges in papillary lesions of the breast. Pathology, 50(1), 100-110. https://doi.org/10.1016/j.pathol.2017.10.005

Papillary lesions of the breast comprise a heterogeneous group of diseases ranging from benign and atypical lesions to malignant tumours including non-invasive and invasive entities. Although diagnosis of papillary lesions featuring typical histologi... Read More about Diagnostic challenges in papillary lesions of the breast.

The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2 (2017)
Journal Article
Abdel-Fatah, T. M., Rees, R. C., Pockley, A. G., Moseley, P., Ball, G. R., Chan, S. Y., …Miles, A. K. (2017). The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2. Oncotarget, 8(68), 112245-112257. https://doi.org/10.18632/oncotarget.22496

Cancer biomarkers that can define disease status and provide a prognostic insight are essential for the effective management of patients with breast cancer (BC). The prevalence, clinicopathological and prognostic significance of PRPF38B expression... Read More about The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.

Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response–targeted therapies in breast cancer (2017)
Journal Article
Naidoo, K., Wai, P. T., Maguire, S. L., Daley, F., Haider, S., Kriplani, D., …Natrajan, R. (2018). Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response–targeted therapies in breast cancer. Molecular Cancer Therapeutics, 17(1), 306-315. https://doi.org/10.1158/1535-7163.mct-17-0760

Disruption of Cyclin-Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and PARP1/2 inhibitors. However, CDK12 has also been proposed as an oncogene in breast cancer. We therefore aimed to assess t... Read More about Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response–targeted therapies in breast cancer.

Altered glutamine metabolism in breast cancer: subtype dependencies and alternative adaptations (2017)
Journal Article
El Ansari, R., McIntyre, A., Craze, M. L., Ellis, I. O., Rakha, E. A., & Green, A. R. (in press). Altered glutamine metabolism in breast cancer: subtype dependencies and alternative adaptations. Histopathology, https://doi.org/10.1111/his.13334

Cancer cells must alter their metabolism in order to satisfy the demands of necessary energy and cellular building blocks. These metabolic alterations are mediated by many oncogenic changes that affect cellular signalling pathways, which result in su... Read More about Altered glutamine metabolism in breast cancer: subtype dependencies and alternative adaptations.

Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms: A Unique Invasive Tumor With Indolent Behavior (2017)
Journal Article
Foschini, M. P., Asioli, S., Foreid, S., Cserni, G., Ellis, I. O., Eusebi, V., & Rosai, J. (2017). Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms: A Unique Invasive Tumor With Indolent Behavior. American Journal of Surgical Pathology, 41(7), 887-895. https://doi.org/10.1097/pas.0000000000000853

Thirteen cases of invasive solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (BPTC) are reported here. Some cases had long-term follow-up. BPTC is a special type of primary breast neoplasm showing a tri... Read More about Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms: A Unique Invasive Tumor With Indolent Behavior.

Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: critical review (2017)
Journal Article
Toss, M., Miligy, I., Thompson, A., Khout, H., Green, A., Ellis, I., & Rakha, E. (2017). Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: critical review. Breast, 35, 151-156. https://doi.org/10.1016/j.breast.2017.07.012

The high proportion of ductal carcinoma in situ (DCIS) presented in mammographic screening and the relatively low risk of progression to invasive disease have raised questions related to overtreatment. Following a review of current DCIS management pr... Read More about Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: critical review.

FOXP1 expression correlates with better prognosis in invasive breast cancer including the ER-positive luminal subtype (2017)
Presentation / Conference Contribution
Joseph, C., Craze, M. L., Nolan, C., Diez-Rodriguez, M., Green, A. R., Rakha, E., …Mukherjee, A. (2017). FOXP1 expression correlates with better prognosis in invasive breast cancer including the ER-positive luminal subtype.

Background: Fork head box P1 (FOXP1) is a FOX family transcription factor influencing ERα;-regulated transcription by interaction with the ERα; related pioneer factor FOXA1. Altered FOXP1 expression is seen in breast and prostate cancers. This study... Read More about FOXP1 expression correlates with better prognosis in invasive breast cancer including the ER-positive luminal subtype.

An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation (2017)
Journal Article
Candido Dos Reis, F. J., Wishart, G. C., Dicks, E. M., Greenberg, D., Rashbass, J., Schmidt, M. K., …Pharoah, P. D. (2017). An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer Research, 19(1), Article 58. https://doi.org/10.1186/s13058-017-0852-3

BACKGROUND: PREDICT is a breast cancer prognostic and treatment benefit model implemented online. The overall fit of the model has been good in multiple independent case series, but PREDICT has been shown to underestimate breast cancer specific morta... Read More about An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation.

Immunoprofile of metaplastic carcinomas of the breast (2017)
Journal Article
Rakha, E. A., Coimbra, N. D., Hodi, Z., Juneinah, E., Ellis, I. O., & Lee, A. H. (2017). Immunoprofile of metaplastic carcinomas of the breast. Histopathology, 70(6), 975-985. https://doi.org/10.1111/his.13159

Aims Metaplastic breast carcinoma (MBC) is a rare type of breast cancer; its diagnosis in routine practice can be challenging, and may require immunohistochemical (IHC) characterization if no conventional invasive or in‐situ carcinoma is present. Pr... Read More about Immunoprofile of metaplastic carcinomas of the breast.

Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer (2017)
Journal Article
Alexander, A., Karakas, C., Chen, X., Carey, J. P., Yi, M., Bondy, M., …Keyomarsi, K. (2017). Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget, 8, 14897-14911. https://doi.org/10.18632/oncotarget.14689

Inflammatory breast cancer (IBC) is a virulent form of breast cancer, and novel treatment strategies are urgently needed. Immunohistochemical analysis of tumors from women with a clinical diagnosis of IBC (n = 147) and those with non-IBC breast cance... Read More about Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.